Compare NAII & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAII | APLT |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 18.0M |
| IPO Year | 1987 | 2019 |
| Metric | NAII | APLT |
|---|---|---|
| Price | $4.77 | $0.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.25 |
| AVG Volume (30 Days) | 16.4K | ★ 11.6M |
| Earning Date | 02-13-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,440,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $2.57 | $0.09 |
| 52 Week High | $4.96 | $1.50 |
| Indicator | NAII | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 76.30 | 28.21 |
| Support Level | $4.43 | $0.09 |
| Resistance Level | $4.80 | $0.10 |
| Average True Range (ATR) | 0.24 | 0.01 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 88.20 | 34.74 |
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.